Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Aromatherapy and Aromatic Plants for the Treatment of Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Clinical Evidence and Possible Mechanisms.

Scuteri D, Morrone LA, Rombolà L, Avato PR, Bilia AR, Corasaniti MT, Sakurada S, Sakurada T, Bagetta G.

Evid Based Complement Alternat Med. 2017;2017:9416305. doi: 10.1155/2017/9416305. Epub 2017 Mar 30. Review.

2.

Management of Behavioral and Psychological Symptoms of Dementia.

Şahin Cankurtaran E.

Noro Psikiyatr Ars. 2014 Dec;51(4):303-312. doi: 10.5152/npa.2014.7405. Epub 2014 Dec 1. Review.

3.

Inequalities in receipt of mental and physical healthcare in people with dementia in the UK.

Cooper C, Lodwick R, Walters K, Raine R, Manthorpe J, Iliffe S, Petersen I.

Age Ageing. 2016 Dec 4. [Epub ahead of print]

4.

Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial.

Chen H, Liu S, Ji L, Wu T, Ji Y, Zhou Y, Zheng M, Zhang M, Xu W, Huang G.

Mediators Inflamm. 2016;2016:5912146. doi: 10.1155/2016/5912146. Epub 2016 Jun 2.

5.

DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing.

Issa NT, Kruger J, Wathieu H, Raja R, Byers SW, Dakshanamurthy S.

BMC Bioinformatics. 2016 May 5;17(1):202. doi: 10.1186/s12859-016-1065-y.

6.

Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis.

Tan L, Tan L, Wang HF, Wang J, Tan CC, Tan MS, Meng XF, Wang C, Yu JT.

Alzheimers Res Ther. 2015 Apr 20;7(1):20. doi: 10.1186/s13195-015-0102-9. eCollection 2015. Retraction in: Tan L, Tan L, Wang HF, Wang J, Tan CC, Tan MS, Meng XF, Wang C, Yu JT. Alzheimers Res Ther. 2016;8(1):28.

7.

Pain, agitation, and behavioural problems in people with dementia admitted to general hospital wards: a longitudinal cohort study.

Sampson EL, White N, Lord K, Leurent B, Vickerstaff V, Scott S, Jones L.

Pain. 2015 Apr;156(4):675-83. doi: 10.1097/j.pain.0000000000000095.

8.

Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review).

Soeiro-DE-Souza MG, Dias VV, Missio G, Balanzá-Martinez V, Valiengo L, Carvalho AF, Moreno RA.

Exp Ther Med. 2015 Mar;9(3):643-652. Epub 2015 Jan 23.

9.

Discontinuing inappropriate medication in nursing home residents (DIM-NHR Study): protocol of a cluster randomised controlled trial.

Wouters H, Quik EH, Boersma F, Nygård P, Bosman J, Böttger WM, Mulder H, Maring JG, Wijma-Vos L, Beerden T, van Doormaal J, Postma MJ, Zuidema SU, Taxis K.

BMJ Open. 2014 Oct 8;4(10):e006082. doi: 10.1136/bmjopen-2014-006082.

10.

Psychiatric issues in cognitive impairment.

Aarsland D, Taylor JP, Weintraub D.

Mov Disord. 2014 Apr 15;29(5):651-62. doi: 10.1002/mds.25873. Review.

11.

Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review.

Seitz DP, Gill SS, Herrmann N, Brisbin S, Rapoport MJ, Rines J, Wilson K, Le Clair K, Conn DK.

Int Psychogeriatr. 2013 Feb;25(2):185-203. doi: 10.1017/S1041610212001627. Epub 2012 Oct 19. Review.

12.

Relapse risk after discontinuation of risperidone in Alzheimer's disease.

Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Levin B.

N Engl J Med. 2012 Oct 18;367(16):1497-507. doi: 10.1056/NEJMoa1114058. Erratum in: N Engl J Med. 2012 Dec 20;367(25):2458.

13.

Atypical antipsychotic use in patients with dementia: managing safety concerns.

Steinberg M, Lyketsos CG.

Am J Psychiatry. 2012 Sep;169(9):900-6. doi: 10.1176/appi.ajp.2012.12030342.

14.

CNS medications as predictors of precipitous cognitive decline in the cognitively disabled aged: a longitudinal population-based study.

Puustinen J, Nurminen J, Vahlberg T, Lyles A, Isoaho R, Räihä I, Kivelä SL.

Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):57-68. doi: 10.1159/000336710. Epub 2012 Mar 16.

15.

Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial.

Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A, Ballard C, Boustani M, Katona C, Livingston G.

PLoS One. 2012;7(5):e35185. doi: 10.1371/journal.pone.0035185. Epub 2012 May 2.

16.

Quality of care provided to people with dementia: utilisation and quality of the annual dementia review in general practice.

Connolly A, Iliffe S, Gaehl E, Campbell S, Drake R, Morris J, Martin H, Purandare N.

Br J Gen Pract. 2012 Feb;62(595):e91-8. doi: 10.3399/bjgp12X625148.

17.

Citalopram for agitation in Alzheimer's disease: design and methods.

Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, Meinert CL, Devanand DP, Yesavage J, Mintzer JE, Schneider LS, Pollock BG, Lyketsos CG; CitAD Research Group.

Alzheimers Dement. 2012;8(2):121-30. doi: 10.1016/j.jalz.2011.01.007. Epub 2012 Feb 1.

18.

Examining multiple sources of differential item functioning on the Clinician & Group CAHPS® survey.

Rodriguez HP, Crane PK.

Health Serv Res. 2011 Dec;46(6pt1):1778-802. doi: 10.1111/j.1475-6773.2011.01299.x. Epub 2011 Aug 11.

19.

Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.

Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Tariot PN, Zheng L, Schneider LS.

Am J Psychiatry. 2011 Aug;168(8):831-9. doi: 10.1176/appi.ajp.2011.08121844. Epub 2011 May 15.

20.

Safety and efficacy of antipsychotic drugs for the behavioral and psychological symptoms of dementia.

Andrade C, Radhakrishnan R.

Indian J Psychiatry. 2009 Jan;51 Suppl 1:S87-92.

Supplemental Content

Support Center